I

Iambic Therapeutics, Inc.

IAMFiled

Iambic Therapeutics, Inc. · Nasdaq Global Select Market · latest filing 2026-10-14

Report source
One-minute decisionBASIC RESEARCHS-1/A · Coverage 70%

Iambic proposes a $15–$17 IPO while remaining pre-commercial and loss-making.

As of the October 8, 2026 preliminary prospectus, Iambic proposed a 9.375 million-share IPO at $15–$17 per share, subject to effectiveness and Nasdaq approval.

Where does the money go?Awaiting verificationS-1/A · 2026-10-08
Ownership and votingAwaiting verified holder data— economic · — voting
Next disclosed checkpointRegistration statement effectiveness, pricing, closing and Nasdaq listing approval remain unconfirmed.S-1/A · 2026-10-08

Capital destination

Awaiting verification

S-1/A · 2026-10-08

Share-type percentages are not net-proceeds percentages. Amounts retain their stated gross/net basis; do not add unlike bases.

Check the source · S-1/A ↗
Next checkRegistration statement effectiveness, pricing, closing and Nasdaq listing approval remain unconfirmed.
Latest filing2026-10-14

Capital destination

Awaiting verification

S-1/A · 2026-10-08

Share-type percentages are not net-proceeds percentages. Amounts retain their stated gross/net basis; do not add unlike bases.

Check the source · S-1/A ↗
BOOKRUNNERS / LEAD UNDERWRITERSBookrunners / lead underwriters
NOT YET DISCLOSED

Names not yet published

Dilution and valuation

IPO priceAwaiting verification
Basic post-offer47,400,796
Fully diluted sharesAwaiting verification
Value—
Dilution and valuation
CalculationSharesValueReference
Post-offer shares · Iambic Therapeutics, Inc.47,400,796—Immediately after offering; no greenshoe exercise · The offering

Basic-price scenario

A verified single offer price and basic post-offer share count are required. This is a data gap, not a paid lock.

Check the source · S-1/A ↗

Holder data awaits verification

Directors, officers, >5% holders and affiliates are expected to beneficially own approximately 28.9% after the offering under stated assumptions. The supplied evidence does not provide aggregate voting percentages or a complete post-offering holder table. · 2026-10-08

Directors, officers, >5% holders and affiliates are expected to beneficially own approximately 28.9% after the offering under stated assumptions. The supplied evidence does not provide aggregate voting percentages or a complete post-offering holder table.

One disclosed holder; not a complete ownership distribution.Check the source · S-1/A ↗

Conditional lock-up timeline

Awaiting verification
Source ↗

Financial quality and runway

Awaiting verification
Source ↗

Latest filing update

Loading saved filing update…

SEC filing history

Loading filing history…

Risk 1

The company has incurred significant losses and negative cash flows and may never become profitable.

SEC EDGAR

S-1/A

2026-10-14

Open SEC filing ↗